Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 9/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843258 | 0.94 | NOTUM (0.34) | NOTUMABL1CTSKMAPK1PKM | |
| SCHEMBL210181 | 0.92 | MAP4K1 (0.38) | MAPK1RAB9AMAP3K5 | |
| SCHEMBL210182 | 0.92 | MAP4K1 (0.38) | MAPK1RAB9AMAP3K5 | |
| SCHEMBL210472 | 0.92 | NOTUM (0.34) | NOTUMABL1CTSKMAPK1PKM | |
| SCHEMBL2840214 | 0.92 | ABL1 (0.32) | NOTUMABL1CTSKMAPK1PKM | |
| SCHEMBL210946 | 0.92 | MAPK1 (0.35) | NOTUMABL1CTSKMAPK1PKM | |
| SCHEMBL210945 | 0.92 | MAPK1 (0.35) | NOTUMABL1CTSKMAPK1PKM | |
| SCHEMBL213602 | 0.91 | ABL1 (0.33) | NOTUMABL1CTSKMAPK1PKM | |
| SCHEMBL213601 | 0.91 | ABL1 (0.33) | NOTUMABL1CTSKMAPK1PKM | |
| SCHEMBL213603 | 0.91 | ABL1 (0.33) | NOTUMABL1CTSKMAPK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | NOTUM 2164/4885ABL1 956/4885CTSK 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.